FOLLOW US

Azzur Group, a key player in pharmaceutical consulting, has filed for Chapter 11 bankruptcy in Delaware, weighed down by at least $100 million in debt. The company, which once rode the wave of pandemic-driven demand for cleanrooms and lab services, is now scrambling to sell off its remaining business units to stay afloat.

In a Sunday bankruptcy filing, Azzur reported assets and liabilities ranging between $100 million and $500 million, including $62.2 million in secured debt and $28.4 million in unsecured obligations. With liquidity running low, the company has secured a $23.5 million debtor-in-possession (DIP) loan to keep operations running as it navigates the bankruptcy process.

The Rise and Fall of Azzur’s Expansion Bet

Founded in 2010, Azzur built its reputation by helping biotech and pharmaceutical firms meet stringent industry regulations. But its bold expansion into cleanrooms-on-demand—sterile environments rented out to pharmaceutical developers—proved to be a double-edged sword.

When COVID-19 triggered a biotech boom, Azzur scaled up aggressively, launching new cleanroom facilities in North Carolina, Massachusetts, and California, backed by a $30.2 million investment from Baird Capital. However, when pandemic-driven demand waned, the company was left with high rent, utilities, and operational costs for underutilized facilities.

The Road to Bankruptcy: Crippling Debt and Missed Expectations

Despite its ambitions, Azzur's cleanroom gamble failed to pay off. By 2023, the company had violated portions of its secured loan agreements, triggering a forbearance agreement that forced Azzur to either secure new investment or sell off assets.

In January, Azzur sold off its lab division for $16 million, using the proceeds to pay down secured debt. But with financial pressures mounting, the company opted to file for bankruptcy to restructure its remaining assets—its consulting arm and cleanrooms-on-demand business.

Auction on the Horizon: Eliquent Sets the Floor

Azzur plans to auction off its assets in early April, with Eliquent Life Sciences stepping in as a stalking horse bidder with a $56 million offer for Azzur’s consulting business. This bid will establish the minimum price for the Chapter 11 auction.

"We believe that Eliquent is the right partner for our consulting business to continue delivering tangible results for clients and provide a runway for success for years to come," said Azzur Group CEO Michael Khavinson.

DIP Financing and Court Oversight

Azzur’s prepetition secured lender, M&T Bank, has agreed to extend a $23.5 million revolving credit facility DIP loan to fund the restructuring. Under the terms of the DIP loan, Azzur must: